LAVIPHARM S.A.
Agreement signed between Lavipharm & Pfizer.
Pfizer Hellas markets Lavipharm's Trinipatch in Greece.
An important co-marketing agreement for the nitroglycerine transdermal system for angina pectoris was signed between Lavipharm and Pfizer Hellas. According to the terms of the agreement, the product will be sold in the Greek market by Pfizer?s sales force and will be marketed under Lavipharm's international trademark Trinipatch. Trinipatch is produced in Lavipharm's plant in Peania and it will be sold by Pfizer Hellas early September.
Lavipharm's Trinipatch is a transdermal delivery system of Nitroglycerine for the treatment of coronary artery disease and heart failure. It is a 3rd generation patch that has a stable therapeutic effect and has been designed to provide continuous and controlled release of nitroglycerine through contact with the skin. Lavipharm markets the same product in Greece under the trademark Nitrong TTS, while it exports it in many countries (Belgium, Netherlands, France, Italy, Spain, Cyprus, Canada), where it is marketed by big pharmaceutical companies.
Transdermal Drug Delivery Systems (TDDS) are one of the pharmaceutical technologies, in which Lavipharm Laboratories Inc., the affiliate company in the US, is actively engaged with great success. TDDS are placed on the skin and allow to certain drug substances to penetrate through the layers of the skin into the bloodstream. This controlled delivery has many benefits compared to other dosage forms, but most importantly, it offers safety and a better quality of life to the patient.
The Chairman and CEO of Lavipharm, Dr. Athanase Lavidas, commented on the new cooperation: "Our agreement with Pfizer, a leading pharmaceutical company worldwide, confirms our investment and achievements in the research and development area. Trinipatch, Lavipharm's international product sold successfully for 10 years now is an important asset in our product portfolio. I believe that this agreement with Pfizer will set the start of a series of new cooperations in the future".
Pfizer's Hellas President and Managing Director, Ms. Katerina Karella, stated: "Pfizer's Hellas cooperation with Lavipharm serves Pfizer's international philosophy, where the area of Research & Development is highly ranked in our corporate strategy. Our cooperation with Lavipharm, a Greek company with an international activity, is an action of trust and support of Greek entrepreneurship and the innovative initiatives of local companies".
Pfizer Inc. was founded in 1849 and today is present in more than 85 countries internationally. With products that hold the first position in their therapeutic category and are marketed in more than 150 countries, and innovative Research and Development programs of new ones, Pfizer holds a leading position in the pharmaceutical area worldwide.
Implementing its vision "together for a healthier world" and with products addressed to cardiovascular and metabolism system, the central nervous and respiratory system, products for arthritis, pain management, allergies, infections and diseases, and products in the areas of endocrinology, urology, ophthalmology and oncology, Pfizer improves human life worldwide. Moreover, its animal health department offers a broad range of animal vaccines and medicines for more than 30 kinds of both pets and farm animals.
Lavipharm, founded in 1911, is an integrated Group of companies engaged in the research, development, production, import, marketing, sales and provision of logistics services of pharmaceutical, dermocosmetic and healthcare products in Greece with a strong international presence. Lavipharm S.A., the mother company, is listed on the Athens Stock Exchange (ASE: LAVI) since November 1995. In Greece, it offers products developed in-house and high level services not only to the pharmacist but the consumer as well. Internationally, it cooperates for the marketing and sales of its product portfolio with the largest pharmaceutical and cosmetic companies in the world. In 2007, consolidated turnover under International Financial Reporting Standards (IFRS), exceeded 248 million Euros. With facilities in Greece, Cyprus, France and the USA, Lavipharm engages more than 800 employees worldwide.
Lavipharm's Trinipatch is a transdermal delivery system of Nitroglycerine for the treatment of coronary artery disease and heart failure. It is a 3rd generation patch that has a stable therapeutic effect and has been designed to provide continuous and controlled release of nitroglycerine through contact with the skin. Lavipharm markets the same product in Greece under the trademark Nitrong TTS, while it exports it in many countries (Belgium, Netherlands, France, Italy, Spain, Cyprus, Canada), where it is marketed by big pharmaceutical companies.
Transdermal Drug Delivery Systems (TDDS) are one of the pharmaceutical technologies, in which Lavipharm Laboratories Inc., the affiliate company in the US, is actively engaged with great success. TDDS are placed on the skin and allow to certain drug substances to penetrate through the layers of the skin into the bloodstream. This controlled delivery has many benefits compared to other dosage forms, but most importantly, it offers safety and a better quality of life to the patient.
The Chairman and CEO of Lavipharm, Dr. Athanase Lavidas, commented on the new cooperation: "Our agreement with Pfizer, a leading pharmaceutical company worldwide, confirms our investment and achievements in the research and development area. Trinipatch, Lavipharm's international product sold successfully for 10 years now is an important asset in our product portfolio. I believe that this agreement with Pfizer will set the start of a series of new cooperations in the future".
Pfizer's Hellas President and Managing Director, Ms. Katerina Karella, stated: "Pfizer's Hellas cooperation with Lavipharm serves Pfizer's international philosophy, where the area of Research & Development is highly ranked in our corporate strategy. Our cooperation with Lavipharm, a Greek company with an international activity, is an action of trust and support of Greek entrepreneurship and the innovative initiatives of local companies".
Pfizer Inc. was founded in 1849 and today is present in more than 85 countries internationally. With products that hold the first position in their therapeutic category and are marketed in more than 150 countries, and innovative Research and Development programs of new ones, Pfizer holds a leading position in the pharmaceutical area worldwide.
Implementing its vision "together for a healthier world" and with products addressed to cardiovascular and metabolism system, the central nervous and respiratory system, products for arthritis, pain management, allergies, infections and diseases, and products in the areas of endocrinology, urology, ophthalmology and oncology, Pfizer improves human life worldwide. Moreover, its animal health department offers a broad range of animal vaccines and medicines for more than 30 kinds of both pets and farm animals.
Lavipharm, founded in 1911, is an integrated Group of companies engaged in the research, development, production, import, marketing, sales and provision of logistics services of pharmaceutical, dermocosmetic and healthcare products in Greece with a strong international presence. Lavipharm S.A., the mother company, is listed on the Athens Stock Exchange (ASE: LAVI) since November 1995. In Greece, it offers products developed in-house and high level services not only to the pharmacist but the consumer as well. Internationally, it cooperates for the marketing and sales of its product portfolio with the largest pharmaceutical and cosmetic companies in the world. In 2007, consolidated turnover under International Financial Reporting Standards (IFRS), exceeded 248 million Euros. With facilities in Greece, Cyprus, France and the USA, Lavipharm engages more than 800 employees worldwide.